NMR study on the major components in hematoporphyrin derivative YHPD

The hematoporphyrin derivative YHPD, a China-made product, has been clinically used in photodynamic therapy of tumors as a good photosensitizing drug. The NMR study on the structure of its major components is reported here. In terms of high performance liquid chromatography (HPLC) four major components A, B, C and D were isolated. The NMR results showed that the component A is O-acetylhematoporphyrin, B and C are two isomers of vinyldeuteroporphyrin. The spectra of 2-dimensional homonuclear correlation NMR, 2-dimensional NOE (nuclear overhauser enhancement), 13C-NMR and off-resonance as well as FAB (fast atom bombarding) mass spectrum of component D indicate that it is a protoporphyrin dimer linked by carbon-carbon bond. This finding may provide a chemical basis for understanding the difference in biological activity between YHPD and other foreign commercial HPD, as well as the composition of clinically used alkali-treated HPD and its effective component.

Effects of ginsenosides on release of [3H]norepinephrine from rat vas deferens and portal vein

The effects of ginsenosides (G) on the release of [3H]norepinephrine ([ 3H]NE) from the isolated rat vas deferens (RVD) and portal vein (RPV) preloaded with [3H]NE were studied, G (100 micrograms/ml) did not affect the spontaneous or high potassium (H-K+, 60 mmol/L)- and tyramine (Tyr 10 mumol/L)-evoked release of [3H]NE, but obviously blunted the phentolamine (Phe 10 mumol/L)-induced increase in [3H]NE release from RVD and enhanced the isoprenaline (Iso 0.1 mumol/L)-augmented [3H]NE release from RPV evoked by H-K+. It is still not known whether G can bind with adrenoceptors. We infer that G may act as a modulator in sensitizing both presynaptic alpha 2- and beta-receptors.

A study on serum cancer-suppressive peptide

A peptide which was isolated from serum of cancer-bearing mice has an activity to kill cancer cells in vitro, but little effect on bone marrow cells. This peptide was named Serum Cancer-Suppressive Peptide (SCSP). SCSP can be crystallized and still has the activity to kill the cancer cells. It consists of more than ten kinds of amino acids with molecular weight about 2000-3000 daltons estimated by SDS-polyacrylamide gel electrophoresis. An antiserum was prepared from rabbits immunized with SCSP and the corresponding IgG could be obtained from the antiserum. The titers of SCSP in some cells of the normal and cancer-bearing mice were estimated by passive hemagglutination method. The results showed that the SCSP titer in spleen is much higher than those in muscle, liver and ascites tumor cells. The results suggest that SCSP is probably produced by spleen cells.

Mosaicism or pseudomosaicism: the problem of hypermodal cells in amniotic fluid cell culture

A series of 2029 consecutive amniotic fluid specimens studied for prenatal genetic diagnosis were reviewed and reassessed so as to evaluate the frequency and clinical significance of hypermodal cells in amniotic fluid cell cultures. Hypermodal cells were defined as those with more than 46 chromosomes, and were characterized by an additional structurally normal or structurally abnormal chromosome. Of 2029 specimens, 47 (2.31 per cent) contained a total of 167 hypermodal cells. True fetal mosaicism was detected in three cases (0.14 per cent). All had hypermodal cells in more than one culture flask or colony which contained the same aberrant chromosome complement. In all but one case the babies were normal when only one cell was hypermodal, or when several cells were hypermodal but present in only one colony or one culture vessel. One case had an extra No. 20 chromosome in one cell. Although the child had multiple anomalies, they were not characteristic of trisomy 20, and subsequent chromosomal study on the baby postnatally revealed a 46,XX karyotype. The in situ coverslip technique is recommended as the preferred method for prenatal diagnosis, and it is useful as an aid in differentiating true mosaicism from pseudomosaicism.

Evaluation of inorganic pyrophosphate in amniotic fluid as a mode of prenatal diagnosis of osteogenesis imperfecta

Using a modified procedure by Solomons and Styner (1969), an evaluation of inorganic pyrophosphate (PPi) was performed on the amniotic fluid of two fetuses at risk for osteogenesis imperfecta (OI) at 14 1/2 weeks gestation. The parents of both cases had a previous child with OI, Type II. The normal control group at 14-16 weeks gestation had PPi values ranging from 22.0-59.2 micrograms/100 ml, with a mean of 38.6 +/- 9.51 micrograms/100 ml. In each at-risk fetus, the amniotic fluid PPi value was within normal range. The first baby was born phenotypically normal at term. Intrauterine radiographic and fetal sonograms were done on the second fetus at approximately 19 weeks gestation. Both showed evidence of OI, Type II. The pregnancy was terminated at 21 weeks. Radiologic studies of the aborted fetus were consistent with OI, Type II. Our results indicate that the evaluation of PPi levels in amniotic fluid is not the method of choice for prenatal diagnosis of OI.